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Abstract: Healthcare-associated infections (HAIs) have been increasing during recent decades,
leading to long hospital stays and high morbidity and mortality rates. The usage of antibiotics
therapy against these infections is enhancing the emergence of more multiple-drug resistant strains,
in particular in Staphylococcus epidermidis. Hence, this study focused on the resistance pattern
of S. epidermidis isolates from clinical settings and its association with phenotypic and molecular
traits. Our results showed that HAIs were more prevalent among infants and older adults, and the
most frequent type of HAI was central line-associated bloodstream infection. Half of the patients
received antibiotic therapy before laboratory diagnosis. Preceding microbiological diagnosis, the
number of patients receiving antibiotic therapy increased by 29.1%. Eighty-six per cent of the
clinical isolates presented a multidrug resistance (MDR) profile, and a quarter were strong biofilm
producers. Furthermore, polysaccharide intercellular adhesin (PIA)-dependent biofilms presented
higher biomass production (p = 0.0041) and a higher rate of antibiotic non-susceptibility than PIA-
independent biofilms, emphasizing the role of icaABDC operon in infection severity. Therefore, this
study suggests that a thorough understanding of the phenotypic and molecular traits of the bacterial
cause of the HAIs may lead to a more suitable selection of antibiotic therapy, improving guidance
and outcome assessment.
Keywords: antibiotic non-susceptibility; biofilm formation; bacterial infections; coagulase-negative
staphylococcus (CONS)
1. Introduction
As part of the human skin microbiota, the coagulase-negative Staphylococcus epidermidis
is now considered an opportunistic pathogen responsible for many healthcare-associated
infections (HAIs), mainly those related to indwelling medical devices [1]. The length of
catheterization and the overuse or improper use of antibiotics are associated with signifi-
cant morbidity and mortality, mostly among immunocompromised, critically ill patients or
very young and very old patients [2]. The last Portuguese national surveillance report on
healthcare infections revealed an overall prevalence of 7.8% [3], with respiratory and blood-
stream infections by coagulase-negative staphylococci, mainly S. epidermidis, being the
most common occurrence [3,4]. Taking into consideration that multidrug resistance (MDR)
among staphylococcal species is increasing [5–7], the study of such infections is of high im-
portance. Worldwide, methicillin/oxacillin resistance which is encoded by the mecA gene
has now been reported to range from 75% to 90% in many hospitals [8–10]. A study con-
cerning S. epidermidis isolates and conducted in 2012 in a single-center Portuguese hospital
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facility revealed a mecA prevalence of around 80%, similar to the reported mecA prevalence
in S. aureus [11,12]. Although acquired antimicrobial resistance compromises the choice of
adequate therapy [13], biofilm formation enhances this problem by affecting the efficacy
of the administrated treatment, leading to persistent infections [14]. S. epidermidis strains
are known to vary in their ability to form biofilms and several genes have been shown to
influence this multifactorial process [15]. Among these, the most extensively studied is the
icaADBC operon, responsible for the synthesis of polysaccharide intercellular adhesin (PIA)
and considered the main factor mediating biofilm growth [16]. The aap (accumulation-
associated protein) [17] and bhp (bap-homologous protein) genes [18] are also involved in
and considered important genetic determinants of S. epidermidis biofilm development in a
PIA-independent manner. Despite the high rates of antimicrobial resistance observed in
Portugal and its clinical impact [12], there is a lack of available information relating to the
molecular and phenotypic traits of S. epidermidis clinical isolates, especially those related
to antibiotic resistance and biofilm formation. Given the importance of biofilm-associated
infections and growing multidrug resistance (MDR) among staphylococcal species [19],
this study aims at phenotypic and genetic evaluation of S. epidermidis isolates from a
tertiary-care hospital of northern Portugal, namely determining the non-susceptible pattern
of those, and assesses its association with the presence of biofilm-mediated genes and
biofilm-forming capacity.
2. Materials and Methods
2.1. Isolation and Identification of Clinical Staphylococcus epidermidis Strains
A total of 86 S. epidermidis isolates were collected at different hospital wards from a
700-bed tertiary-care teaching hospital in Porto (Portugal) that handles about 35,000 inpatients
admissions per year. Those S. epidermidis clinical isolates came from patients aged from 0 to
94 years old with a diagnosis of HAIs associated with device colonization, clinically and labo-
ratory confirmed, following Infectious Diseases Society of America (IDSA) guidelines [20].
HAIs were defined as a localized or systemic condition resulting from an adverse reaction
to the presence of an infectious agent(s) or its toxin(s). That condition occurred 48 h or
more after hospital admission and was neither present nor incubating at the time of admis-
sion [21]. Patients’ clinical and demographic data including medical comorbidities were
collected under the approval of the Ethics Committee Board of Hospital de Santo António,
Porto Hospital Centre (Reference 015/09: 014-DEFI/014-CES). Each isolate was identified at
the species level using the commercially available VITEK® 2 identification system using the
gram-positive ID card (BioMérieux) and subsequently by matrix-assisted laser desorption
ionization-time of flight (BioMérieux), according to the manufacturer’s instructions.
2.2. Antimicrobial Susceptibility Testing
Resistance to penicillin, clindamycin, erythromycin, daptomycin, fusidic acid, fos-
fomycin, gentamicin, levofloxacin, moxifloxacin, linezolid, rifampin, tetracycline, tigecy-
cline, vancomycin, teicoplanin and trimethoprim-sulfamethoxazole was determinate by
VITEK® 2 using the P619 panel (BioMérieux) and MIC values interpreted according to
CLSI recommendations. S. epidermidis strains were considered as MDR if non-susceptible
to at least one agent in three or more antimicrobial categories according to standardized
international terminology [22]. Clinical isolates with an intermediate or resistant phenotype
to a given antibiotic agent were considered non-susceptible.
2.3. Quantification of In Vitro Biofilm Formation
Biofilm cultures were performed in batch mode as previously described [23]. Further-
more, quantitative determination of in vitro biofilm biomass was performed as previously
described by Stepanović [24] with some modifications. Briefly, after incubation time, the
bacterial cells in suspension were carefully removed and each well was washed twice with
200 µL of 0.9% NaCl. Afterwards, 100 µL of 99.9% methanol (Fisher Scientific) was added
to each well and let sit for 15 min to fix the biofilm. Methanol was then removed, and
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the plate was left to air dry. The fixed bacteria biofilm cells were stained with 200 µL of
1% (v/v) crystal violet (Merck) per well, for 5 min. Excess crystal violet was removed by
gently washing each well twice with distilled water and filled with 160 µL of 33% (v/v)
glacial acetic acid (Fisher Scientific) to solubilize the crystal violet staining. The optical
density (OD) was measured at 570 nm using a microtiter plate reader (Tecan) and set as
a proxy for the amount of biomass present in a biofilm. Sixteen replicates of each isolate
per biofilm assay were included and a minimum of three independent assays were carried
out. Moreover, a biofilm producer (S. epidermidis ATCC 35984) and a non-biofilm producer
(S. epidermidis ATCC 12228) were also included. The OD570 nm average of each isolate was
compared with the mean OD570 nm of S. epidermidis ATCC 12228 (ODc = 0.1) and used to
define the cutoff value to organize the clinical isolates into three main categories depending
on whether they produced a strong and thick biofilm (SP), a moderate biofilm (MP) or
weak/non-biofilm (NP). To simplify the data analysis, the level of biofilm production was
classified as follows: ODC ≥ OD < 2 × ODC (weak/non-producers), 2 × ODC ≤ OD ≤ 5
× ODC (moderate producers) 5 × ODC > OD (strong producers).
2.4. Gene Detection by Polymerase Chain Reaction (PCR)
One to five bacterial colonies of each isolate were inoculated from a TSA agar plate
into 200 µL of nuclease-free water. The cells were lysed by heating at 95 ◦C for 10 min
followed by 5 min on ice. Cellular debris was removed by centrifugation at maximum
speed for 5 min. One µL of the collected supernatant was used as a template for PCR
amplification. For single target amplification, the PCR was performed in an MJ Mini
thermal cycler (Bio-Rad) with a final volume of 10 µL and containing 5 µL of DyNAzyme
II PCR Master Mix 2x (Finnenzymes), 1 µL of primer mixture with a 10 µM concentration
each and 2 µL of nuclease-free water. The primer sequences of the mecA gene and icaA,
aap and bhp biofilm-mediating genes used in this study are listed in Table 1. To minimize
PCR amplification bias and false-negative results, two sets of primers for each tested gene
were used.
Table 1. Oligonucleotide sequences used in polymerase chain reaction (PCR) gene amplification.
Gene Oligonucleotide Sequence (5′ to 3′) PCR Product Size (bp)
PCR amplification of methicillin-resistance gene
mecA set 1
Fw: CCG AAA CAA TGT GGA ATT GG
600Rv: TCA CCT GTT TGA GGG TGG AT
mecA set 2
Fw: GGC CAA TAC AGG AAC AGC AT
425Rv: CTG CAA CGA TTG TGA CAC G
PCR amplification of biofilm-mediated genes
icaA set 1
Fw: TGC ACT CAA TGA GGG AAT CA
417Rv: TCA GGC ACT AAC ATC CAG CA
icaA set 2
Fw: TGC ACT CAA TGA GGG AAT CA
132Rv: TAA CTG CGC CTA ATT TTG GAT T
aap set 1 Fw: GCT CTC ATA ACG CCA CTT GC 617Rv: GGA CAG CCA CCT GGT ACA AC
aap set 2 Fw: GCA CCA GCT GTT GTT GTA CC 199Rv: GCA TGC CTG CTG ATA GTT CA
bhp set 1 Fw: TGG ACT CGT AGC TTC GTC CT 213Rv: TCT GCA GAT ACC CAG ACA ACC
bhp set 2 Fw: CGT TCC CTT GAT TGA GGT GT 404Rv: GTT ACG TGA ACG GGT CGA TT
The PCR program consisted of an initial denaturation step at 94 ◦C for 5 min, followed
by 35 cycles of DNA denaturation at 94 ◦C for 30 sec, primer annealing at 56 ◦C for 30 sec,
and primer extension at 72 ◦C for 45 sec. After the last cycle, a final extension step at 72 ◦C
for 10 min was added. Total PCR products were analyzed by gel electrophoresis with 2%
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agarose (Bio-Rad) stained with Midori Green DNA stain (Nippon Genetics Europe GmbH,
Germany) and visualized by GelDoc® 2000 (Bio-Rad). A 100-bp DNA ladder (NZYTech)
was used as a marker. A mock PCR reaction lacking the DNA template was prepared
and used as a negative PCR control. Besides, S. epidermidis ATCC 35984 was included as
a positive PCR control. The rpoB gene was used as an internal control for each sample.
S. epidermidis isolates were considered to harbor any of the tested genes if having at least
one positive PCR result.
2.5. Statistical Analysis
Statistical analysis of the comparison of categorical variables was performed using the
unpaired t-test, Fisher’s exact test and Pearson’s chi-squared test (χ2). All analyses were
performed using GraphPad Prism version 7 (Trial version, San Diego, CA, USA). The level
of significance was set at p-value < 0.05 and all tests were two-tailed.
3. Results
3.1. Characterization of the Study Population and Antibiotic Therapy
Over 30 months, 86 clinical isolates of S. epidermidis were collected from patients with
a diagnosis of device-related infection and treated in a tertiary-care hospital in Portugal’s
second major city (Porto). The studied patients represented a very heterogeneous group,
comprising patients with distinct ages ranging from newborns to 94 years old, and near half
(43.0%, n = 37) were female patients (Table 2). HAIs were more prevalent among infants and
the elderly, being both considered the most susceptible group because of their long stays
in hospitals and less effective immune systems [25]. Regarding the type of HAIs, central
line-associated bloodstream infections (CLABIs) were by far the most frequently reported
during the period under study, accounting for 60.5% (n = 52) of all clinical infections,
while catheter-associated urinary tract infections (CAUTIs) and respiratory tract infections
respectively accounted for 18.6% (n = 16) and 12.8% (n = 11). Furthermore, CLABIs were
similarly distributed among the different age groups rather than CAUTIs, which were
more prevalent among elders (68.8%). Surgical-site infections (5.8%, n = 5) and skin and
soft tissue infections (2.3%, n = 2) were the less prevalent infections. Before laboratory
diagnosis, 55.8% (n = 48) of the patients received antibiotic therapy, vancomycin being
the most prescribed drug. Preceding microbiological diagnosis, the number of patients
receiving antibiotic therapy increased by 29.1%, with major frequency in older adults, and
among those, near half (48.0%) changed therapeutic after microbiological results.
Table 2. Patients’ clinical and demographic data.
Patients’ Clinical Parameters
Demographic characteristics
Age median (95% CI) in years 46.0 (10.5–75.3)
≤1 year (% of patients) 24.4
>65 years (% of patients) 39.5
Male gender (% of patients) 57.0
Average length of hospitalization from admission to S. epidermidis
Isolation (Number of days) 25.0
Type of HAIs
Central Line-Associated Bloodstream Infection (CLABIs) 60.5
Catheter-associated Urinary Tract Infections (CAUTIs) 18.6
Respiratory Tract Infections (RTIs) 12.8
Surgical Site Infections (SSIs) 8.1
Under antibiotic therapy (% of patients)
Pre-culture 55.8
Post culture 84.9
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3.2. Antibiotic Susceptibility Characteristics
S. epidermidis isolates’ levels of non-susceptibility to at least one agent in three or
more antibiotic categories, hence considered as MDR, were unexpectedly high (86%,
n = 74) and of those, 91.9% carried the mecA gene, and were thus classified as methicillin-
resistant S. epidermidis (MRSE). S. epidermidis isolates lacking mecA gene were considered
as methicillin-susceptible S. epidermidis (MSSE), regardless of the oxacillin susceptibility re-
sults obtained. The analysis of antimicrobial susceptibility profiles revealed that all isolates
were 100% susceptible to vancomycin, daptomycin and tigecycline (Figure 1). Additionally,
linezolid (96.5%, n = 83) and fosfomycin (94.2%, n = 81) also demonstrated high levels of
susceptibility to most of the clinical isolates tested. Seventy-two (83.7%) clinical isolates
also showed a high rate of susceptibility to teicoplanin whereas the other 14 (16.3%) isolates
were non-susceptible. Furthermore, the MDR phenotype was equally distributed among
the different age groups and isolates with distinct biofilm phenotype and molecular traits.
Figure 1. Antibiotic non-susceptible profile of the S. epidermidis isolates. PEN, penicillin; ERY,
Erythromycin; FA, fusidic acid; TET, tetracycline; LVX, levofloxacin; GEN, gentamicin; CLI, clin-
damycin; SXT, trimethoprim/sulfamethoxazole; MXF, moxifloxacin; RIF, rifampicin; TEC, teicoplanin;
FOF, fosfomycin; LZD, linezolid; VAN, vancomycin; DAP, daptomycin; TGC, tigecycline; MDR,
multidrug resistance.
3.3. Phenotypic and Virulence-Associated Genetic Traits
Regarding the biomass production quantified and used to define the biofilm-forming
capacity of the clinical isolates, 24.4% (n = 21) and 61.6% (n = 53) were, respectively, strong and
moderate producers, while 14.0% (n = 12) were considered weak/non-biofilm producers.
Furthermore, the carriage of icaA, aap and bhp biofilm-mediating genes was assessed. The
molecular determination of icaA, aap and bhp genes revealed that aap was the most prevalent
gene, detected in 90.7% (n = 78) of the isolates, followed by icaA accounting for 64.0% (n = 55) and
bhp for 44.2% (n = 38) of the isolates. Of interest, none of the clinical isolates was characterized by
the presence of just a bhp virulence-associated gene. Only 5% (n = 4) of the isolates were negative
for all tested genes (icaA−aap−bhp−). Regarding the genetic combinations, the most frequently
observed was icaA+aap+bhp− (39.5%, n = 34), followed by icaA−aap+bhp+ (22.1%, n = 19) and by
the carriage of the three-gene combination (icaA+aap+bhp+, 19.8%, n = 17). Moreover, all clinical
isolates that were icaA+aap+bhp+ were related with both the MRSE and MDR phenotypes while
only 89% of the icaA−aap+bhp+ isolates demonstrated an MRSE and an MDR phenotype. A
significant difference was found between the amount of biomass formed by PIA-dependent and
PIA-independent clinical isolates [OD570 nm of 0.63± 0.07 vs. 0.32± 0.02, p = 0.0041 unpaired
t-test, respectively].
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3.4. Analysis of Antibiotic Non-Susceptibility Against Biofilm-Forming Capacity and
Biofilm-Mediating Genes
The impact of the biofilm thickness against the antibiotic efficacy was considered
in this study. As expected, the higher rates of non-susceptibility obtained seemed to be
related to strong biofilm producers (Figure 2a). Remarkably, independently of the biofilm
formation capacity and genetic background concerning the biofilm-mediating studied
genes, most of the S. epidermidis isolates seemed to be resilient to fusidic acid. Gentamicin
was demonstrated to have a higher impact in reducing moderate rather than strong biofilms
(p < 0.05, Fisher’s exact test).
Figure 2. Relation between antibiotic non-susceptible profile of the S. epidermidis isolates and: (a) their
biofilm-forming capacity; (b) their genetic profile grouped into two major classes (PIA-dependent—
icaA+, and PIA-independent—icaA−). PEN, penicillin; ERY, Erythromycin; FA, fusidic acid; TET, tetra-
cycline; LVX, levofloxacin; GEN, gentamicin; CLI, clindamycin; SXT, trimethoprim/sulfamethoxazole;
MXF, moxifloxacin; RIF, rifampicin; TEC, teicoplanin; FOF, fosfomycin; LZD, linezolid. None, nega-
tive for all genes (icaA−aap−bhp−).
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S. epidermidis isolates were grouped in two classes for the analysis of their genetic
profile: PIA-dependent (positive for icaA, independent of being positive or negative for aap
and/or bhp—icaA+aap+bhp+; icaA+aap+bhp−; icaA+aap−bhp+ and icaA+aap−bhp−) and PIA-
independent (positive only for aap and/or bhp not icaA—aap+bhp−; aap−bhp+ and aap+bhp+).
The relation of this classification of isolates to their non-susceptible profile demonstrated
that the biofilm-mediated gene icaA seemed to be the main gene responsible for the an-
tibiotics’ failure against the S. epidermidis isolates in this study (Figure 2b). Additionally,
among all antibiotics tested, moxifloxacin (p = 0.0026) and clindamycin (p = 0.0317) were
revealed to be more efficient against S. epidermidis isolates that did not carry the icaA gene.
4. Discussion
Portugal has one of the highest rates of antimicrobial resistance and antibiotic con-
sumption across the European Union [26]. Despite the high prevalence of HAIs in Portugal
(7.8% in 2017; [3]), very limited information is available regarding those caused by biofilm-
forming species, coagulase-negative staphylococci and S. epidermidis in particular [27],
which reinforces the importance of local studies in gathering and analyzing data to provide
local and detailed information regarding opportunistic pathogens. Therefore, this study
was conducted to provide a picture of the non-susceptible patterns of S. epidermidis clinical
isolates from a major tertiary-care hospital and its relationship with phenotypic and/or
molecular traits.
In the present study, CLABIs were the most common type of infection among our
patients’ group. This is not surprising, since S. epidermidis is considered the leading
cause of BSI episodes related or not to a secondary site of infection [26]. One of the risk
factors associated with BSIs seems to be linked to previous antibiotic consumption [28,29],
which is often administrated before microbiological sampling analysis. This exposure
leads to antibiotic resistance and subsequent resistant infections yield higher rates of
morbidity and mortality [30]. The levels of antibiotic consumption prior to microbiology
diagnosis were very high in this hospital (55.8%), as well as the levels of MRSE (91.9%)
(Table 2), somewhat similar to those obtained in an earlier study conducted in a single-
center hospital in the Portuguese capital, Lisbon (79.8% versus 87.2%) [31]. These numbers
suggest that the spread of antibiotic non-susceptibility by the accumulation of resistance
genes (i.e., mecA) is high and might be mostly due to the selective pressure exerted by
the overconsumption of antibiotics among the Portuguese community outside/within
healthcare facilities [4,32]. Similar observations were made in other countries [33–35]. In
fact, numerous ecological studies have shown a clear association between the emergence
of antibiotic resistance and the growing antibiotic overuse and misuse [36]. S. epidermidis,
in particular MRSE strains, are considered reservoirs of antimicrobial resistance genes and
prone to accumulate these genes [36,37], which is a cause of major concern as it is often
associated with a higher risk of therapeutic failure. Vancomycin alone or in combination
was the drug of choice, as recommended as a first-line treatment for infections caused by
MRSE [38,39], and it remains a valued choice as all S. epidermidis isolates were susceptible to
vancomycin. Additionally, the susceptibility rates to daptomycin and tigecycline were also
high (Figure 1), a fact consistent with other studies [40,41]; reinforcing that those antibiotics
remain important alternatives for antibiotic therapy against S. epidermidis infections at
least in this hospital’s service community. Linezolid and fosfomycin also demonstrated
high levels of efficacy against S. epidermidis isolates. It was already reported that linezolid
exhibits excellent activity against staphylococci species, being the only oxazolidinone
approved for clinical use. Although linezolid resistance among S. epidermidis remains
uncommon worldwide, it has increasingly been reported among some European countries,
consequently its usage should be carefully evaluated [35]. Conversely, very high levels of
non-susceptibility were found among the β-lactam antibiotics such as penicillin (91.9%),
but also erythromycin (77.9%) and tetracycline (69.8%). While of great concern, this fact
was therefore expected as many reports conveyed high and growing rates of resistance
among those antibiotics [34,42].
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Since propensity for biofilm formation has an enormous clinical impact on bacteria
resilience and consequently drug resistance [43,44], the in vitro biofilm-forming capacity
and the carriage of icaA, aap and bhp biofilm-mediated genes of each clinical isolate was
evaluated. Similar to previous studies [45,46], the majority of the studied clinical isolates of
the S. epidermidis study population exhibited biofilm-forming in vitro capacity, and among
those 27.9% formed thick biofilm. S. epidermidis strains are known to vary in their ability
to form biofilm and several genes are known to impact this multifactorial process. The
icaA gene is known to play a major role in the formation of more dense/robust biofilms
and thus commonly related to infection severity and inefficacy of drug treatment [47,48].
Among the studied clinical isolates, 64.0% presented in their genome the icaA gene, and its
presence was mainly among strong biofilm producers. These results are in agreement with
previous studies confirming that icaA is a key element in the biofilm formation process and
has major relevance in the pathogenesis of S. epidermidis [42,49].
Therefore, other genes are known to also be involved in biofilm formation, such as
aap and bhp, and their expression seems to be related to the formation of more thinner
and proteinaceous biofilms—known as PIA-independent [27,50]. In accordance, these
genes, alone or in combination, were present in 31.4% of clinical isolates and were mainly
related to moderate biofilm-formation capacity, therefore confirming their importance
in S. epidermidis-related infections. Despite app gene being the most common virulent
gene in S. epidermidis infection, strains carrying only aap gene, demonstrated a diminished
potential to form in vitro biofilms. Since none of the clinical isolates presented only the bhp
gene, its role could not confirm any link to biofilm accumulation, also confirming other
observations [15].
The analysis of antibiotic efficiency against S. epidermidis biofilms revealed that the
non-susceptibility to penicillin and erythromycin is widely spread among strains in this
hospital, and the action/non-action of those antibiotics seems to be independent of the
biofilm thickness (Figure 2a). Similar results were found in a study conducted by Cabrera-
Contreras et al., wherein 245 S. epidermidis strains isolated from nosocomial infections
were analyzed, and which found high rates of resistance among both biofilm and non-
biofilm producers (penicillin ≈97%, erythromycin ≈70%) [51]. In contrast, fosfomycin and
linezolid seemed to be effective against S. epidermidis-related infections, affecting near to
97–98% of strong and moderate producers and yet presenting high susceptibility rates.
Remarkably, linezolid and fosfomycin in combination demonstrated a synergetic effect
against S. epidermidis isolates in a recent study [52,53], suggesting that these antibiotics can
still be used in combination (at reduced concentrations) for treatment when monotherapy is
not possible. Within the biofilm producers, 82.5% of isolates presented an MDR phenotype,
which is a major red flag warning to surveillance and should prompt the design of more
efficient programs to effectively tackle and block the rise of antibiotic resistance in this
local hospital.
The relationship between the antibiotics’ non-susceptibility and the carriage of biofilm-
mediating genes was also explored (Figure 2b). Overall, it seems that PIA-independent
biofilms are more susceptible to all tested antibiotics than PIA-dependent biofilms, a result
in agreement with others [54,55] and expected, since lack of the icaA gene leads to the
development of less thick biofilms [56], which in turn allows more effective penetration
of the antibiotic in the biofilm structure. However, this rate of higher non-susceptibility
in PIA-dependent biofilms seemed to be remarkable for moxifloxacin (p = 0.0026) and
clindamycin (p = 0.0317) comparatively to PIA-independent strains. Rifampicin seems to
also have a higher inhibitory effect against S. epidermidis isolates forming PIA-independent
biofilms. Therefore, it was already pointed out that rifampicin has the broadest range of
action against S. epidermidis isolates’ biofilms, alone or in combination with clindamycin
or with gentamicin, as it penetrates the biofilm structure, more easily reaching the bac-
teria within [57]. However, the efficiency of the antibiotic combination will be therefore
dependent on the molecular and phenotypic traits of the S. epidermidis strains.
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5. Conclusions
Portugal has some of the highest rates of HAIs, antibiotic consumption and antimi-
crobial resistance across the European Union [3]. Despite this high prevalence [4], limited
information is available concerning HAIs’ determinants and etiological agents associated
with these types of infections, more specifically concerning S. epidermidis—known as a
major nosocomial pathogen. To our knowledge, this is the first study addressing clinical,
microbiological and molecular information of S. epidermidis-causing HAIs associated with
medical devices in Portugal. This report reinforces the urgent need for knowledge to fight
against HAIs associated with medical devices and caused by biofilm-forming species and
suggests that the screening of biofilm-mediated genes may lead to a more suitable selection
of antimicrobial therapy, thus reducing the overuse/misuse of antibiotics and MDR spread
in alignment with Sustainable Development Goals 2030.
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